Promising therapeutic strategies have been developed to target EGFR in HNSCC by monoclonal antibodies or small-molecule tyrosine kinase inhibitors (6) that showed limited clinical efficacy due to very heterogeneous and low response rates or the development of drug resistance (7). The gene discussed is EGFR; the disease is head and neck squamous cell carcinoma.